18 Jan Anocca
Mark Farmery, Ph.D., Chief Development Officer
April 16 | 4:45pm | Salone dei Cavalieri, Section 2
Stockholm, Sweden
(Private)
Anocca, a Swedish biotechnology company, has built end-to-end capabilities to enable systematic T-cell receptor-engineered T-cell therapy (TCR-T) development at scale to redefine the treatment of solid tumor cancers. Based on programmable human cells, its proprietary technology platform recreates T-cell immunity and precisely maps HLA-peptide T-cell targets on cancer cells and identifies specific and potent TCRs that recognize those targets. Anocca uses its platform to generate TCR asset libraries that are matched to a patient’s tumor profile and deployed in personalized TCR-T cell therapies. Anocca’s pipeline comprises over 40 TCR assets that target driver mutations, dysregulated tumor-specific genes, and onco-viral antigens. Using a non-viral gene-editing approach, Anocca’s integrated in-house process development and cGMP manufacturing capabilities enable the clinical development of its TCR-T cell therapy products. VIDAR-1, a multi-asset TCR-T program in advanced pancreatic cancer with KRAS mutations, is the company’s first clinical program and, pending approval, is about to start.
